Background Mesalazine is the most commonly prescribed medication for mild to moderate
ulcerative colitis. It is generally well tolerated with some reported side effects. Aim To …

Abnormal liver biochemical tests are present in up to 30% of patients with inflammatory
bowel disease (IBD), and therefore become a diagnostic challenge. Liver and biliary tract …

Metabolic processes utilize a variety of differing and contrasting biochemical routes to
enable synthesis of degradation and activation or deactivation of substances; in addition …

Background Extraintestinal manifestations are frequent in inflammatory bowel diseases
(IBD). Most studies published so far focused on viral hepatitis and liver toxicity of IBD‐related …

Of the numerous medicinal agents, chemicals, and herbal remedies in existence, more than
600 are recognized as producing hepatic injury. 2o5 The incidence of drug-induced liver …

Inflammatory bowel diseases are associated with various hepatobiliary disorders, reported
both in Crohn's disease and ulcerative colitis. They may occur at any moment in the natural …

Patients with inflammatory bowel disease (IBD) often have other immune-mediated
inflammatory diseases (IMIDs), and the prevalence of any IMID is higher in IBD patients than …

OBJECTIVES The relationship between abnormal hepatic biochemistries and inflammatory
bowel disease (IBD) is unclear. We determined the prevalence of abnormal hepatic …

Hepatobiliary manifestations are common in inflammatory bowel disease (IBD), with 30% of
patients presenting abnormal liver tests and 5% developing chronic liver disease. They …

A considerable number of patients with inflammatory bowel disease (IBD) experience
extraintestinal manifestations (EIMs), which can present either before or after IBD diagnosis …